C6orf165 Inhibitors
Chemical inhibitors of C6orf165 can modulate the protein's activity through various signaling pathways by targeting specific kinases and enzymes that regulate its function. Wortmannin and LY294002 are both phosphoinositide 3-kinases (PI3K) inhibitors. By blocking PI3K, these chemicals prevent the formation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a vital second messenger involved in the activation of AKT. This action leads to a decrease in the phosphorylation and activation of downstream proteins that are part of the PI3K/AKT/mTOR pathway, to which C6orf165 activity is linked. Rapamycin specifically inhibits mTOR, a central component of the same pathway, and thus indirectly reduces the functional activity of C6orf165 by dampening the pathway's output.
Further down the signaling cascade, PD98059 and U0126 function as MEK inhibitors, blocking the MAPK/ERK pathway, which is another crucial route for cellular signal transduction. These inhibitors prevent the activation of MEK1/2, resulting in reduced ERK activity and subsequently lowering the functional activity of proteins regulated by this pathway, including C6orf165. Similarly, SB203580 and SP600125 target the p38 MAPK and JNK pathways, respectively, adding to the spectrum of kinase inhibition that can influence C6orf165 function. SB203580 specifically inhibits p38 MAPK, while SP600125 targets JNK, both of which are kinases that can impact the activity of diverse cellular proteins. Dasatinib and PP2 inhibit Src family kinases, leading to reduced phosphorylation of many substrates, including those that may regulate C6orf165 activity. Go6983, a protein kinase C (PKC) inhibitor, suppresses the activity of PKC isoforms, potentially decreasing the activity of proteins within PKC-regulated pathways where C6orf165 might play a role. Lastly, SL327 and Sorafenib, both of which are also MEK inhibitors, contribute to the inhibition of the MAPK/ERK pathway, further establishing the control over the enzymatic cascades that could regulate the functional activity of C6orf165.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in signal transduction pathways. Inhibition of PI3K by Wortmannin could lead to reduced phosphorylation and activation of downstream effectors that are critical for the function of C6orf165, thereby functionally inhibiting C6orf165. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents the formation of PIP3, a crucial signaling molecule. This inhibition decreases AKT phosphorylation, which can lead to reduced activity of downstream proteins including C6orf165, thus functionally inhibiting it. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR, which is part of the PI3K/AKT/mTOR pathway, a pathway known to regulate protein synthesis and cell proliferation. By inhibiting mTOR, Rapamycin can diminish the activity of proteins regulated by this pathway, including C6orf165. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway by inhibiting the activation of MEK1/2. As ERK is downstream of MEK, this inhibition could reduce the functional activity of proteins like C6orf165 that are regulated by the MAPK/ERK pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor that prevents the activation of ERK1/2. The inhibition of the MAPK/ERK pathway can lead to a decrease in functional activity of C6orf165 if it is regulated by this pathway. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK can reduce the activity of substrates regulated by this kinase, which could include proteins like C6orf165, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which may lead to reduced activity of transcription factors and other proteins regulated by JNK signaling. This could result in functional inhibition of C6orf165 if it is regulated by JNK pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor, and by inhibiting Src kinases, it could reduce the phosphorylation and activation of downstream proteins that are crucial for the function of C6orf165, thus functionally inhibiting it. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is another Src family kinase inhibitor, and its action in inhibiting these kinases can lead to decreased activity of proteins like C6orf165 that are regulated by Src signaling, resulting in functional inhibition. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a protein kinase C (PKC) inhibitor. PKC is involved in a broad range of cellular signaling pathways, and its inhibition can lead to decreased activity of proteins regulated by PKC, potentially including C6orf165, thus inhibiting its function. | ||||||